Search the Newsreel

What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday?

Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

EPRX Stock Price and Chart — TSX:EPRX

This article provides a detailed overview of Eupraxia Pharmaceuticals, Inc. (EPRX) stock on the Toronto Stock Exchange, including its current price, historical performance, key financial statistics, and analyst ratings. It highlights the company's focus on drug delivery technology for conditions like arthritis and chronic …

Eupraxia Q2 EPS beats estimate despite wider net loss

Eupraxia Pharmaceuticals Inc. reported Q2 2026 EPS of $(0.23), surpassing analyst estimates of $(0.25) despite a wider net loss of $14.5 million, primarily due to increased R&D spending for its lead EoE asset, EP-104GI. The company maintains strong liquidity with $133.6 million in cash …

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported a quarterly loss of $0.23 per share, surpassing analyst estimates by $0.02. Shares saw a modest increase of 0.6% to $6.70, and the company maintains strong financial liquidity. Analyst sentiment for EPRX is mixed but generally positive, with a "Moderate …

Eupraxia Pharmaceuticals (NASDAQ: EPRX) widens loss to $27.1M while raising $58.6M

Eupraxia Pharmaceuticals reported a widened net loss of $27.1 million for the six months ended June 30, 2026, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its liquidity by raising $58.6 million …

Will Eupraxia Pharmaceuticals Inc (EPRX) Beat Earnings Estimates in Its Next Report?

Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Eupraxia Pharmaceuticals Inc (EPRX), highlighting analyst ratings, target prices, and historical/projected EPS and revenue growth. Nine analysts currently rate EPRX as a "Buy" with a target price of USD 16.444, suggesting a 146.91% upside. The article also …

Eupraxia Pharmaceuticals Inc (EPRX) Stock News Today

This article provides current stock information for Eupraxia Pharmaceuticals Inc (EPRX), showing its stock price, market capitalization, and a brief overview of available financial data sections on the TradingKey platform. It indicates that more news regarding EPRX is expected soon. The content primarily serves …

Eupraxia Pharmaceuticals (NASDAQ: EPRX) sets up US$300M mixed securities shelf

Eupraxia Pharmaceuticals Inc. has filed a short form base shelf prospectus and accompanying Form F-10 to register up to US$300,000,000 in mixed securities, including common shares, preferred shares, debt securities, warrants, subscription receipts, and units. These securities may be offered over a 25-month period …

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $18.00, significantly higher than its current price of $6.40. Despite the positive analyst sentiment, the company remains unprofitable, reporting a quarterly loss of $0.23 …

Bloom Burton Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $14

Bloom Burton has reiterated its Buy rating for Eupraxia Pharmaceuticals (EPRX.US) and maintained its target price at $14. This indicates continued confidence in the company's prospects by the investment firm.

276,000 Shares in Eupraxia Pharmaceuticals Inc. $EPRX Acquired by DV Trading LLC

DV Trading LLC has acquired 276,000 shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in the first quarter, representing a significant stake in the company. Other institutional investors have also increased their positions. Despite these acquisitions, Eupraxia Pharmaceuticals shares opened lower at $6.40, and the company reported …

Ally Bridge Group NY LLC Raises Stock Holdings in Eupraxia Pharmaceuticals Inc. $EPRX

EPRX Forecast — Price Target — Prediction for 2027

Eupraxia Pharmaceuticals (EPRX) Slips 2.19% as Stock Tests Key Support at $5.94 - Cumulative Volume

EPRX: Positive clinical data and strong cash reserves position the company for multi-year growth

Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing

EPRX: Q4 2025 saw clinical advances, a doubled cash position, and increased R&D-driven net loss

EPRX: Advanced clinical pipeline and raised $140M+ in equity, ending 2025 with $80.6M cash

Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26%

EPRX: Strong 52-week clinical data and $80.5M financing extend cash runway into 2028

EPRX: Q2 net loss widened to $8.7M as clinical trials advanced; cash runway extends into Q3 2026

EPRX: Strong clinical progress and cash position offset by higher net loss and tariff uncertainties

EPRX: Improved net loss, strong cash position, and clinical progress support continued development

EPRX: Reduced net loss, strong clinical data, and new funding position the company for continued growth

EPRX: Strong clinical progress and improved financials position the company for continued growth